Yun Wang

Yun Wang

Auto-generated profile, based on publicly available information

Yun Wang

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2025 in Cancer Research
Verified
Journal Article
Open access
JLJiahuan Lu
Jiahuan Lu
TCThomas Ting-Hei Chan
Thomas Ting-Hei Chan
YWYun Wang
Yun Wang
JWJingya Wang
Jingya Wang
ZXZhewen Xiong
Zhewen Xiong
JZJingying Zhou
Jingying Zhou
Turning immunologically “cold” tumors “hot” is required for effective immune checkpoint inhibitor (ICI) treatment in hepatocellular carcinoma (HCC). Here, we identified Fas-associated death domain (FADD) as a key molecule upregulated in HCC with dense tumor-infiltrating CD8+ T cells and better response to ICIs. CRISPR-mediated knockout of Fadd in murine HCC cells led to increased tumor weights in immunocompetent, but not immunodeficient, mice. FADD deficiency also led to decreased intratumoral infiltration of CD8+ T cells and lower production of IFN-γ and TNF-ɑ. Mechanistically, phosphorylated FADD translocated into the nucleus where it interacted with Sam68 to upregulate NF-κB-induced transcription of CCL5, thereby promoting CD8+ T cell recruitment. Treatment with anti-PD-1 triggered FADD phosphorylation in ICI-sensitive tumors, which was not observed in ICI-resistant tumors. FADD activation through genetic or pharmacologic approaches overcame ICI resistance in orthotopic and spontaneous HCC mouse models in vivo. Together, these findings provide insights into combinatory immunotherapy approaches for HCC patients.

15 September 2025
Verified
Other
Open access
JLJiahuan Lu
Jiahuan Lu
TCThomas Ting-Hei Chan
Thomas Ting-Hei Chan
YWYun Wang
Yun Wang
JWJingya Wang
Jingya Wang
ZXZhewen Xiong
Zhewen Xiong
JZJingying Zhou
Jingying Zhou
Figure S2 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors

15 September 2025
Verified
Other
Open access
JLJiahuan Lu
Jiahuan Lu
TCThomas Ting-Hei Chan
Thomas Ting-Hei Chan
YWYun Wang
Yun Wang
JWJingya Wang
Jingya Wang
ZXZhewen Xiong
Zhewen Xiong
JZJingying Zhou
Jingying Zhou
Figure S11 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors


15 September 2025
Verified
Other
Open access
JLJiahuan Lu
Jiahuan Lu
TCThomas Ting-Hei Chan
Thomas Ting-Hei Chan
YWYun Wang
Yun Wang
JWJingya Wang
Jingya Wang
ZXZhewen Xiong
Zhewen Xiong
JZJingying Zhou
Jingying Zhou
Figure S5 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors

15 September 2025
Verified
Other
Open access
JLJiahuan Lu
Jiahuan Lu
TCThomas Ting-Hei Chan
Thomas Ting-Hei Chan
YWYun Wang
Yun Wang
JWJingya Wang
Jingya Wang
ZXZhewen Xiong
Zhewen Xiong
JZJingying Zhou
Jingying Zhou
Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors